Page 3 - Division Of Hematology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond

Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Sanjal desaiUniversity of minnesotaDivision of hematology

Future Indications and Frontline Potential of Cilta-Cel in Multiple Myeloma: Insights From Dr Binod Dhakal

Future Indications and Frontline Potential of Cilta-Cel in Multiple Myeloma: Insights From Dr Binod Dhakal
ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.

Binod dhakalJanssen johnsonDivision of hematologyCollege of wisconsinLegend biotechMedical college

Tumor mutations may not predict response to immunotherapy, study finds

The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a commonly prescribed type of immunotherapy, a team led by UT Southwestern Medical Center researchers reported in a retrospective study.

David hsiehMaishara muquithUt southwestern medical centerCaris precision oncology allianceDrug administrationHaroldc simmons comprehensive cancer centerDivision of hematologyNature cancerMedical centerAssistant professorInternal medicineComprehensive cancer center

Eckfeldt Looks Towards the Future of AML and MDS Care

Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.

United statesUniversity of minnesotaCraig eckfeldtInternational journal of molecular sciencesM health fairview cancerDivision of hematologyInternational journalMolecular sciencesOnclive stateScience summit

Tumor mutations may not predict response to immuno

The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a

United statesZhao zhuMagdalena espinozaMaishara muquithJakel hamonDavid hsiehChildren medical center research instituteLeader of the developmentHaroldc simmons comprehensive cancer centerDrug administrationDivision of hematologySouthwestern medical centerResearch institute of texasCaris precision oncology allianceSimmons cancer centerCancer research program